Pharsight

Vanda Pharms Inc patents expiration

1. Fanapt patents expiration

FANAPT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138432 VANDA PHARMS INC Methods for the administration of iloperidone
Sep, 2025

(1 year, 6 months from now)

US8586610 VANDA PHARMS INC Methods for the administration of iloperidone
Nov, 2027

(3 years from now)

US9157121 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Apr, 2030

(6 years from now)

US8652776 VANDA PHARMS INC Prediction of QT prolongation based on SNP genotype
Aug, 2030

(6 years from now)

US8999638 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Oct, 2030

(6 years from now)

US9074255 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2030

(6 years from now)

US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Jan, 2031

(6 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Feb, 2031

(6 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2031

(7 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine; Method of treating schizophrenia by administering ilo...

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

2. Hetlioz patents expiration

HETLIOZ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 3 months ago)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24 ho...

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

3. Hetlioz Lq patents expiration

HETLIOZ LQ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 3 months ago)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime...

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

Family Patents